The final, formatted version of the article will be published soon.
ORIGINAL RESEARCH article
Front. Mol. Biosci.
Sec. Molecular Diagnostics and Therapeutics
Volume 11 - 2024 |
doi: 10.3389/fmolb.2024.1434023
LncRNA ILF3AS1, MMP3, MMP9 and miRNA-212 are emerging novel biomarkers for childhood Epilepsy
Provisionally accepted- 1 Faculty of Medicine for Girls, Al-Azhar University, Cairo, Cairo, Egypt
- 2 Faculty of Medicine, Al-Azhar University, Gaza, Egypt
- 3 Faculty of Medicine of Boys, Al-Azhar University, Cairo, Beni Suef, Egypt
- 4 Department of Internal Medicine, Faculty of Medicine, Assiut University, Assiut, Asyut, Egypt
- 5 College of Medicine, Princess Nourah bint Abdulrahman University, Riyadh, Riyadh, Saudi Arabia
- 6 Department of Microbiology and Immunology, Faculty of Pharmacy, Sphinx University, Assiut, Beni Suef, Egypt
- 7 Department of Pharmacology, Faculty of Medicine, Assiut University, Assiut., Assiut, Egypt
- 8 Department of Clinical Pathology, Faculty of Medicine, Ain Shams University, Cairo, Beni Suef, Egypt
- 9 Medical biochemistry and molecular biology department, faculty of Medicine, Assiut university, Assiut, Egypt
- 10 Department of Medical Biochemistry and Molecular Biology, Armed Forces College of Medicine (AFCM),Cairo, Cairo, Egypt
Background: Approximately 70 million people suffer from epilepsy worldwide. Infants representing significant percentage of cases. Therefore, there is a significant need for a greater understanding of the pathophysiology of epilepsy using laboratory and radiological methods for early detection and optimized management. Interleukin enhancer-binding factor 3-antisense RNA l (ILF3-AS1) is a LnRNA that enhances the expression of matrix metalloproteinase 3 (MMP3) and matrix metalloproteinase 9 (MMP9), which are all thought to be epileptogenic.We aimed to assess serum expression of LncRNA ILF3AS1, MMP3, MMP9, and microRNA 212 (miRNA-212) as predictive biomarkers in children with epilepsy and assessing their correlations with magnetic resonance imaging (MRI) findings.Fivty children with epilepsy and 50 healthy controls. Serum expression of LncRNA ILF3ASI and miRNA-212 were estimated by s q-PCR. Serum concentrations of MMP3 and MMP9 were estimated by ELISA in parallel with the magnetic resonance imaging (MRI) findings and different baseline biochemical parameters of all included subjects.The study revealed significantly higher levels of Lnc RNA ILF3AS1, MMP3, and MMP9 and lower levels of miR-212 in children with epilepsy compered to controls. Fold-change miR-212 was a significant negative predictor (OR= 0.153, P=0.000). The receiver operating characteristic (ROC) curve showed that the areas under the curves (AUC) for MMP3, MMP9, lncRNA ILF3AS1, and fold-change miRNA212 were 0.659, 0.738, 0.656 and 0.965, respectively. Brain lesions were detected in 15 patients (30%) with epilepsy, whereas the remaining 35 patients (70%) had normal results.LncRNA ILF3AS1 serum levels among children with epilepsy children were higher than those in the control group and were associated with the upregulation of MMP3 and MMP9 and the downregulation of miR-212 expression, suggesting their predictive utility in monitoring the development of epilepsy and that a treatment plan that focuses on the ILF3-AS1/miR-212/MMP3 & 9 axis may be an effective strategy for treating epilepsy.
Keywords: Epilepsy, Lnc RNA ILF3AS1, mi RNA 212, MMP3, MMP9 & MRI
Received: 17 May 2024; Accepted: 17 Jul 2024.
Copyright: © 2024 Mohammed, Emam, Mohammed, Abd Elalim, Mansour, Nasr, Ghamry, Alkhawagah, Fathy, Elattar, Abish, Hussein, Zaghloul, Khairallah, Alharbi, Seif Eldin, Dawood, Sabet, Gamea, Elshishtawy Ibrahim, Mosa and Dahpy. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Marwa A. Dahpy, Medical biochemistry and molecular biology department, faculty of Medicine, Assiut university, Assiut, Egypt
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.